Sooyun Caroline Tavolacci

Dr. Sooyun Caroline Tavolacci

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 April 2023 in Clinical Lung Cancer
Verified
Journal Article
Closed access
NMNoy Meshulami
Noy Meshulami
STSooyun Caroline Tavolacci
Sooyun Caroline Tavolacci
DMDiego de Miguel-Perez
Diego de Miguel-Perez
CRChristian Rolfo
Christian Rolfo
PMPhilip C. Mack
Philip C. Mack
FHFred R. Hirsch
Fred R. Hirsch

2 September 2024 in Clinical Transplantation
Verified
Journal Article
Closed access
JSJunichi Shimamura
Junichi Shimamura
KOKenji Okumura
Kenji Okumura
RMRyosuke Misawa
Ryosuke Misawa
RBRoxana Bodin
Roxana Bodin
SNSeigo Nishida
Seigo Nishida
SOSuguru Ohira
Suguru Ohira

17 September 2024 in Artificial Organs
Verified
Journal Article
Closed access
SKShazli Khan
Shazli Khan
AIAmeesh Isath
Ameesh Isath
VGVasiliki Gregory
Vasiliki Gregory
GEGuy Elgar
Guy Elgar
ALAvi Levine
Avi Levine
SOSuguru Ohira
Suguru Ohira

6 August 2025 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
STSooyun Caroline Tavolacci
Sooyun Caroline Tavolacci
AIAmeesh Isath
Ameesh Isath
GRGabriel Rodriguez
Gabriel Rodriguez
JSJunichi Shimamura
Junichi Shimamura
SLSteven L. Lansman
Steven L. Lansman
SOSuguru Ohira
Suguru Ohira

9 December 2024 in Clinical Transplantation
Verified
Journal Article
Closed access
STSooyun Caroline Tavolacci
Sooyun Caroline Tavolacci
VGVasiliki Gregory
Vasiliki Gregory
KOKenji Okumura
Kenji Okumura
AIAmeesh Isath
Ameesh Isath
JSJunichi Shimamura
Junichi Shimamura
SOSuguru Ohira
Suguru Ohira

26 June 2024 in Vaccines
Verified
Journal Article
Open access
PDF file
PMPhilip Christopher Mack
Philip Christopher Mack
CHChih-Yuan Hsu
Chih-Yuan Hsu
ARAnanda M. Rodilla
Ananda M. Rodilla
JGJorge E Gomez
Jorge E Gomez
JCJazz Cagan
Jazz Cagan
YSYu Shyr
Yu Shyr
In patients with lung cancer (LC), understanding factors that impact the dynamics of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) anti-spike antibody (SAb) titers over time is critical, but challenging, due to evolving treatments, infections, vaccinations, and health status. The objective was to develop a time-dependent regression model elucidating individual contributions of factors influencing SAb levels in LC patients using a prospective, longitudinal, multi-institutional cohort study initiated in January 2021. The study evaluated 296 LC patients—median age 69; 55% female; 50% stage IV. Blood samples were collected every three months to measure SAb levels using FDA-approved ELISA. Asymptomatic and unreported infections were documented through measurement of anti-nucleocapsid Ab levels (Meso Scale Discovery). Associations between clinical characteristics and titers were evaluated using a time-dependent linear regression model with a generalized estimating equation (GEE), considering time-independent variables (age, sex, ethnicity, smoking history, histology, and stage) and time-dependent variables (booster vaccinations, SARS-CoV-2 infections, cancer treatment, steroid use, and influenza vaccination). Significant time-dependent effects increasing titer levels were observed for prior SARS-CoV-2 infection (p < 0.001) and vaccination/boosters (p < 0.001). Steroid use (p = 0.043) and chemotherapy (p = 0.033) reduced titer levels. Influenza vaccination was associated with increased SAb levels (p < 0.001), independent of SARS-CoV-2 vaccine boosters. Prior smoking significantly decreased titers in females (p = 0.001). Age showed no association with titers. This GEE-based linear regression model unveiled the nuanced impact of multiple variables on patient anti-spike Ab levels over time. After controlling for the major influences of vaccine and SARS-CoV-2 infections, chemotherapy and steroid use were found to have negatively affected titers. Smoking in females significantly decreased titers. Surprisingly, influenza vaccinations were also significantly associated, likely indirectly, with improved SARS-CoV-2 titers.